Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market 2026 by Company, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global Amyotrophic Lateral Sclerosis (ALS) Treatment market size was valued at US$ 387 million in 2025 and is forecast to a readjusted size of US$ 655 million by 2032 with a CAGR of 7.9% during review period.
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig?s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
The cause is not known in 90% to 95% of cases. The remaining 5?10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.
GlobalAmyotrophic Lateral Sclerosis (ALS) Treatment key players include Mitsubishi Tanabe Pharma, Sanofi, etc. Global top two manufacturers hold a share over 80%.
North America is the largest market, with a share about 60%, followed by Japan, and Europe, both have a share over 20 percent.
In terms of product, Edaravone (Radicava) is the largest segment, with a share over 75%. And in terms of application, the largest application is Hospital, followed by Drugs Store, etc.
This report is a detailed and comprehensive analysis for global Amyotrophic Lateral Sclerosis (ALS) Treatment market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Amyotrophic Lateral Sclerosis (ALS) Treatment market size and forecasts, in consumption value ($ Million), 2021-2032
Global Amyotrophic Lateral Sclerosis (ALS) Treatment market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Amyotrophic Lateral Sclerosis (ALS) Treatment market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Amyotrophic Lateral Sclerosis (ALS) Treatment market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Amyotrophic Lateral Sclerosis (ALS) Treatment market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig?s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
The cause is not known in 90% to 95% of cases. The remaining 5?10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.
GlobalAmyotrophic Lateral Sclerosis (ALS) Treatment key players include Mitsubishi Tanabe Pharma, Sanofi, etc. Global top two manufacturers hold a share over 80%.
North America is the largest market, with a share about 60%, followed by Japan, and Europe, both have a share over 20 percent.
In terms of product, Edaravone (Radicava) is the largest segment, with a share over 75%. And in terms of application, the largest application is Hospital, followed by Drugs Store, etc.
This report is a detailed and comprehensive analysis for global Amyotrophic Lateral Sclerosis (ALS) Treatment market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Amyotrophic Lateral Sclerosis (ALS) Treatment market size and forecasts, in consumption value ($ Million), 2021-2032
Global Amyotrophic Lateral Sclerosis (ALS) Treatment market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Amyotrophic Lateral Sclerosis (ALS) Treatment market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Amyotrophic Lateral Sclerosis (ALS) Treatment market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
- To determine the size of the total market opportunity of global and key countries
- To assess the growth potential for Amyotrophic Lateral Sclerosis (ALS) Treatment
- To forecast future growth in each product and end-use market
- To assess competitive factors affecting the marketplace
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Amyotrophic Lateral Sclerosis (ALS) Treatment market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Riluzole
- Edaravone (Radicava)
- Other
- Hospital
- Drugs Store
- Other
- Mitsubishi Tanabe Pharma
- Sanofi
- Mylan Pharma
- Apotex
- Glemark Generics
- Covis Pharma
- Sun Pharma
- Lunan Pharma
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
- Chapter 1, to describe Amyotrophic Lateral Sclerosis (ALS) Treatment product scope, market overview, market estimation caveats and base year.
- Chapter 2, to profile the top players of Amyotrophic Lateral Sclerosis (ALS) Treatment, with revenue, gross margin, and global market share of Amyotrophic Lateral Sclerosis (ALS) Treatment from 2021 to 2026.
- Chapter 3, the Amyotrophic Lateral Sclerosis (ALS) Treatment competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
- Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
- Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Amyotrophic Lateral Sclerosis (ALS) Treatment market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
- Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
- Chapter 12, the key raw materials and key suppliers, and industry chain of Amyotrophic Lateral Sclerosis (ALS) Treatment.
- Chapter 13, to describe Amyotrophic Lateral Sclerosis (ALS) Treatment research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Amyotrophic Lateral Sclerosis (ALS) Treatment by Type
1.3.1 Overview: Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Type in 2025
1.3.3 Riluzole
1.3.4 Edaravone (Radicava)
1.3.5 Other
1.4 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Application
1.4.1 Overview: Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application: 2021 Versus 2025 Versus 2032
1.4.2 Hospital
1.4.3 Drugs Store
1.4.4 Other
1.5 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size & Forecast
1.6 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast by Region
1.6.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region: 2021 VS 2025 VS 2032
1.6.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region, (2021-2032)
1.6.3 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Prospect (2021-2032)
1.6.4 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Prospect (2021-2032)
1.6.5 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Prospect (2021-2032)
1.6.6 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Prospect (2021-2032)
1.6.7 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 Mitsubishi Tanabe Pharma
2.1.1 Mitsubishi Tanabe Pharma Details
2.1.2 Mitsubishi Tanabe Pharma Major Business
2.1.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
2.1.4 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Mitsubishi Tanabe Pharma Recent Developments and Future Plans
2.2 Sanofi
2.2.1 Sanofi Details
2.2.2 Sanofi Major Business
2.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
2.2.4 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Sanofi Recent Developments and Future Plans
2.3 Mylan Pharma
2.3.1 Mylan Pharma Details
2.3.2 Mylan Pharma Major Business
2.3.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
2.3.4 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Mylan Pharma Recent Developments and Future Plans
2.4 Apotex
2.4.1 Apotex Details
2.4.2 Apotex Major Business
2.4.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
2.4.4 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Apotex Recent Developments and Future Plans
2.5 Glemark Generics
2.5.1 Glemark Generics Details
2.5.2 Glemark Generics Major Business
2.5.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
2.5.4 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Glemark Generics Recent Developments and Future Plans
2.6 Covis Pharma
2.6.1 Covis Pharma Details
2.6.2 Covis Pharma Major Business
2.6.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
2.6.4 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Covis Pharma Recent Developments and Future Plans
2.7 Sun Pharma
2.7.1 Sun Pharma Details
2.7.2 Sun Pharma Major Business
2.7.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
2.7.4 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Sun Pharma Recent Developments and Future Plans
2.8 Lunan Pharma
2.8.1 Lunan Pharma Details
2.8.2 Lunan Pharma Major Business
2.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
2.8.4 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Lunan Pharma Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of Amyotrophic Lateral Sclerosis (ALS) Treatment by Company Revenue
3.2.2 Top 3 Amyotrophic Lateral Sclerosis (ALS) Treatment Players Market Share in 2025
3.2.3 Top 6 Amyotrophic Lateral Sclerosis (ALS) Treatment Players Market Share in 2025
3.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Overall Company Footprint Analysis
3.3.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Region Footprint
3.3.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Company Product Type Footprint
3.3.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value and Market Share by Type (2021-2026)
4.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Application (2021-2026)
5.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2021-2032)
6.2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2021-2032)
6.3 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country
6.3.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2021-2032)
6.3.2 United States Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
6.3.3 Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
6.3.4 Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2021-2032)
7.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2021-2032)
7.3 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country
7.3.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2021-2032)
7.3.2 Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
7.3.3 France Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
7.3.5 Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
7.3.6 Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region
8.3.1 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Region (2021-2032)
8.3.2 China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
8.3.3 Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
8.3.4 South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
8.3.5 India Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
8.3.7 Australia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2021-2032)
9.2 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2021-2032)
9.3 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country
9.3.1 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2021-2032)
9.3.2 Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
9.3.3 Argentina Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country
10.3.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2021-2032)
10.3.2 Turkey Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
10.3.4 UAE Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Drivers
11.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Restraints
11.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Chain
12.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Upstream Analysis
12.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Midstream Analysis
12.4 Amyotrophic Lateral Sclerosis (ALS) Treatment Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Amyotrophic Lateral Sclerosis (ALS) Treatment by Type
1.3.1 Overview: Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Type in 2025
1.3.3 Riluzole
1.3.4 Edaravone (Radicava)
1.3.5 Other
1.4 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Application
1.4.1 Overview: Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application: 2021 Versus 2025 Versus 2032
1.4.2 Hospital
1.4.3 Drugs Store
1.4.4 Other
1.5 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size & Forecast
1.6 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast by Region
1.6.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region: 2021 VS 2025 VS 2032
1.6.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region, (2021-2032)
1.6.3 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Prospect (2021-2032)
1.6.4 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Prospect (2021-2032)
1.6.5 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Prospect (2021-2032)
1.6.6 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Prospect (2021-2032)
1.6.7 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 Mitsubishi Tanabe Pharma
2.1.1 Mitsubishi Tanabe Pharma Details
2.1.2 Mitsubishi Tanabe Pharma Major Business
2.1.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
2.1.4 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Mitsubishi Tanabe Pharma Recent Developments and Future Plans
2.2 Sanofi
2.2.1 Sanofi Details
2.2.2 Sanofi Major Business
2.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
2.2.4 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Sanofi Recent Developments and Future Plans
2.3 Mylan Pharma
2.3.1 Mylan Pharma Details
2.3.2 Mylan Pharma Major Business
2.3.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
2.3.4 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Mylan Pharma Recent Developments and Future Plans
2.4 Apotex
2.4.1 Apotex Details
2.4.2 Apotex Major Business
2.4.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
2.4.4 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Apotex Recent Developments and Future Plans
2.5 Glemark Generics
2.5.1 Glemark Generics Details
2.5.2 Glemark Generics Major Business
2.5.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
2.5.4 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Glemark Generics Recent Developments and Future Plans
2.6 Covis Pharma
2.6.1 Covis Pharma Details
2.6.2 Covis Pharma Major Business
2.6.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
2.6.4 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Covis Pharma Recent Developments and Future Plans
2.7 Sun Pharma
2.7.1 Sun Pharma Details
2.7.2 Sun Pharma Major Business
2.7.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
2.7.4 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Sun Pharma Recent Developments and Future Plans
2.8 Lunan Pharma
2.8.1 Lunan Pharma Details
2.8.2 Lunan Pharma Major Business
2.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
2.8.4 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Lunan Pharma Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of Amyotrophic Lateral Sclerosis (ALS) Treatment by Company Revenue
3.2.2 Top 3 Amyotrophic Lateral Sclerosis (ALS) Treatment Players Market Share in 2025
3.2.3 Top 6 Amyotrophic Lateral Sclerosis (ALS) Treatment Players Market Share in 2025
3.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Overall Company Footprint Analysis
3.3.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Region Footprint
3.3.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Company Product Type Footprint
3.3.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value and Market Share by Type (2021-2026)
4.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Application (2021-2026)
5.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2021-2032)
6.2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2021-2032)
6.3 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country
6.3.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2021-2032)
6.3.2 United States Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
6.3.3 Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
6.3.4 Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2021-2032)
7.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2021-2032)
7.3 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country
7.3.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2021-2032)
7.3.2 Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
7.3.3 France Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
7.3.5 Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
7.3.6 Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region
8.3.1 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Region (2021-2032)
8.3.2 China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
8.3.3 Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
8.3.4 South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
8.3.5 India Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
8.3.7 Australia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2021-2032)
9.2 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2021-2032)
9.3 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country
9.3.1 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2021-2032)
9.3.2 Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
9.3.3 Argentina Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country
10.3.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2021-2032)
10.3.2 Turkey Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
10.3.4 UAE Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Drivers
11.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Restraints
11.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Chain
12.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Upstream Analysis
12.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Midstream Analysis
12.4 Amyotrophic Lateral Sclerosis (ALS) Treatment Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 3. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Region (2021-2026) & (USD Million)
Table 4. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Region (2027-2032) & (USD Million)
Table 5. Mitsubishi Tanabe Pharma Company Information, Head Office, and Major Competitors
Table 6. Mitsubishi Tanabe Pharma Major Business
Table 7. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
Table 8. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 9. Mitsubishi Tanabe Pharma Recent Developments and Future Plans
Table 10. Sanofi Company Information, Head Office, and Major Competitors
Table 11. Sanofi Major Business
Table 12. Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
Table 13. Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 14. Sanofi Recent Developments and Future Plans
Table 15. Mylan Pharma Company Information, Head Office, and Major Competitors
Table 16. Mylan Pharma Major Business
Table 17. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
Table 18. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 19. Apotex Company Information, Head Office, and Major Competitors
Table 20. Apotex Major Business
Table 21. Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
Table 22. Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 23. Apotex Recent Developments and Future Plans
Table 24. Glemark Generics Company Information, Head Office, and Major Competitors
Table 25. Glemark Generics Major Business
Table 26. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
Table 27. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 28. Glemark Generics Recent Developments and Future Plans
Table 29. Covis Pharma Company Information, Head Office, and Major Competitors
Table 30. Covis Pharma Major Business
Table 31. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
Table 32. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 33. Covis Pharma Recent Developments and Future Plans
Table 34. Sun Pharma Company Information, Head Office, and Major Competitors
Table 35. Sun Pharma Major Business
Table 36. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
Table 37. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 38. Sun Pharma Recent Developments and Future Plans
Table 39. Lunan Pharma Company Information, Head Office, and Major Competitors
Table 40. Lunan Pharma Major Business
Table 41. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
Table 42. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 43. Lunan Pharma Recent Developments and Future Plans
Table 44. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million) by Players (2021-2026)
Table 45. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Players (2021-2026)
Table 46. Breakdown of Amyotrophic Lateral Sclerosis (ALS) Treatment by Company Type (Tier 1, Tier 2, and Tier 3)
Table 47. Market Position of Players in Amyotrophic Lateral Sclerosis (ALS) Treatment, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 48. Head Office of Key Amyotrophic Lateral Sclerosis (ALS) Treatment Players
Table 49. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Company Product Type Footprint
Table 50. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Company Product Application Footprint
Table 51. Amyotrophic Lateral Sclerosis (ALS) Treatment New Market Entrants and Barriers to Market Entry
Table 52. Amyotrophic Lateral Sclerosis (ALS) Treatment Mergers, Acquisition, Agreements, and Collaborations
Table 53. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (USD Million) by Type (2021-2026)
Table 54. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Share by Type (2021-2026)
Table 55. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Forecast by Type (2027-2032)
Table 56. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2021-2026)
Table 57. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Forecast by Application (2027-2032)
Table 58. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2021-2026) & (USD Million)
Table 59. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2027-2032) & (USD Million)
Table 60. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2021-2026) & (USD Million)
Table 61. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2027-2032) & (USD Million)
Table 62. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2021-2026) & (USD Million)
Table 63. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2027-2032) & (USD Million)
Table 64. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2021-2026) & (USD Million)
Table 65. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2027-2032) & (USD Million)
Table 66. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2021-2026) & (USD Million)
Table 67. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2027-2032) & (USD Million)
Table 68. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2021-2026) & (USD Million)
Table 69. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2027-2032) & (USD Million)
Table 70. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2021-2026) & (USD Million)
Table 71. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2027-2032) & (USD Million)
Table 72. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2021-2026) & (USD Million)
Table 73. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2027-2032) & (USD Million)
Table 74. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Region (2021-2026) & (USD Million)
Table 75. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Region (2027-2032) & (USD Million)
Table 76. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2021-2026) & (USD Million)
Table 77. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2027-2032) & (USD Million)
Table 78. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2021-2026) & (USD Million)
Table 79. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2027-2032) & (USD Million)
Table 80. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2021-2026) & (USD Million)
Table 81. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2027-2032) & (USD Million)
Table 82. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2021-2026) & (USD Million)
Table 83. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2027-2032) & (USD Million)
Table 84. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2021-2026) & (USD Million)
Table 85. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2027-2032) & (USD Million)
Table 86. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2021-2026) & (USD Million)
Table 87. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2027-2032) & (USD Million)
Table 88. Global Key Players of Amyotrophic Lateral Sclerosis (ALS) Treatment Upstream (Raw Materials)
Table 89. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Typical Customers
Table 1. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 3. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Region (2021-2026) & (USD Million)
Table 4. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Region (2027-2032) & (USD Million)
Table 5. Mitsubishi Tanabe Pharma Company Information, Head Office, and Major Competitors
Table 6. Mitsubishi Tanabe Pharma Major Business
Table 7. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
Table 8. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 9. Mitsubishi Tanabe Pharma Recent Developments and Future Plans
Table 10. Sanofi Company Information, Head Office, and Major Competitors
Table 11. Sanofi Major Business
Table 12. Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
Table 13. Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 14. Sanofi Recent Developments and Future Plans
Table 15. Mylan Pharma Company Information, Head Office, and Major Competitors
Table 16. Mylan Pharma Major Business
Table 17. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
Table 18. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 19. Apotex Company Information, Head Office, and Major Competitors
Table 20. Apotex Major Business
Table 21. Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
Table 22. Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 23. Apotex Recent Developments and Future Plans
Table 24. Glemark Generics Company Information, Head Office, and Major Competitors
Table 25. Glemark Generics Major Business
Table 26. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
Table 27. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 28. Glemark Generics Recent Developments and Future Plans
Table 29. Covis Pharma Company Information, Head Office, and Major Competitors
Table 30. Covis Pharma Major Business
Table 31. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
Table 32. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 33. Covis Pharma Recent Developments and Future Plans
Table 34. Sun Pharma Company Information, Head Office, and Major Competitors
Table 35. Sun Pharma Major Business
Table 36. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
Table 37. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 38. Sun Pharma Recent Developments and Future Plans
Table 39. Lunan Pharma Company Information, Head Office, and Major Competitors
Table 40. Lunan Pharma Major Business
Table 41. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
Table 42. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 43. Lunan Pharma Recent Developments and Future Plans
Table 44. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million) by Players (2021-2026)
Table 45. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Players (2021-2026)
Table 46. Breakdown of Amyotrophic Lateral Sclerosis (ALS) Treatment by Company Type (Tier 1, Tier 2, and Tier 3)
Table 47. Market Position of Players in Amyotrophic Lateral Sclerosis (ALS) Treatment, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 48. Head Office of Key Amyotrophic Lateral Sclerosis (ALS) Treatment Players
Table 49. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Company Product Type Footprint
Table 50. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Company Product Application Footprint
Table 51. Amyotrophic Lateral Sclerosis (ALS) Treatment New Market Entrants and Barriers to Market Entry
Table 52. Amyotrophic Lateral Sclerosis (ALS) Treatment Mergers, Acquisition, Agreements, and Collaborations
Table 53. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (USD Million) by Type (2021-2026)
Table 54. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Share by Type (2021-2026)
Table 55. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Forecast by Type (2027-2032)
Table 56. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2021-2026)
Table 57. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Forecast by Application (2027-2032)
Table 58. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2021-2026) & (USD Million)
Table 59. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2027-2032) & (USD Million)
Table 60. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2021-2026) & (USD Million)
Table 61. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2027-2032) & (USD Million)
Table 62. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2021-2026) & (USD Million)
Table 63. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2027-2032) & (USD Million)
Table 64. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2021-2026) & (USD Million)
Table 65. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2027-2032) & (USD Million)
Table 66. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2021-2026) & (USD Million)
Table 67. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2027-2032) & (USD Million)
Table 68. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2021-2026) & (USD Million)
Table 69. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2027-2032) & (USD Million)
Table 70. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2021-2026) & (USD Million)
Table 71. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2027-2032) & (USD Million)
Table 72. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2021-2026) & (USD Million)
Table 73. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2027-2032) & (USD Million)
Table 74. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Region (2021-2026) & (USD Million)
Table 75. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Region (2027-2032) & (USD Million)
Table 76. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2021-2026) & (USD Million)
Table 77. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2027-2032) & (USD Million)
Table 78. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2021-2026) & (USD Million)
Table 79. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2027-2032) & (USD Million)
Table 80. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2021-2026) & (USD Million)
Table 81. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2027-2032) & (USD Million)
Table 82. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2021-2026) & (USD Million)
Table 83. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2027-2032) & (USD Million)
Table 84. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2021-2026) & (USD Million)
Table 85. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2027-2032) & (USD Million)
Table 86. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2021-2026) & (USD Million)
Table 87. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2027-2032) & (USD Million)
Table 88. Global Key Players of Amyotrophic Lateral Sclerosis (ALS) Treatment Upstream (Raw Materials)
Table 89. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Typical Customers
LIST OF FIGURES
Figure 1. Amyotrophic Lateral Sclerosis (ALS) Treatment Picture
Figure 2. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Type in 2025
Figure 4. Riluzole
Figure 5. Edaravone (Radicava)
Figure 6. Other
Figure 7. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 8. Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Application in 2025
Figure 9. Hospital Picture
Figure 10. Drugs Store Picture
Figure 11. Other Picture
Figure 12. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 13. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 14. Global Market Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 15. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Region (2021-2032)
Figure 16. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Region in 2025
Figure 17. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 18. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 19. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 20. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 21. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 22. Company Three Recent Developments and Future Plans
Figure 23. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Players in 2025
Figure 24. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 25. Market Share of Amyotrophic Lateral Sclerosis (ALS) Treatment by Player Revenue in 2025
Figure 26. Top 3 Amyotrophic Lateral Sclerosis (ALS) Treatment Players Market Share in 2025
Figure 27. Top 6 Amyotrophic Lateral Sclerosis (ALS) Treatment Players Market Share in 2025
Figure 28. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Share by Type (2021-2026)
Figure 29. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share Forecast by Type (2027-2032)
Figure 30. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Share by Application (2021-2026)
Figure 31. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share Forecast by Application (2027-2032)
Figure 32. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Type (2021-2032)
Figure 33. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Application (2021-2032)
Figure 34. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Country (2021-2032)
Figure 35. United States Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 36. Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 37. Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 38. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Type (2021-2032)
Figure 39. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Application (2021-2032)
Figure 40. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Country (2021-2032)
Figure 41. Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 42. France Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 43. United Kingdom Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 44. Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 45. Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 46. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Type (2021-2032)
Figure 47. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Application (2021-2032)
Figure 48. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Region (2021-2032)
Figure 49. China Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 50. Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 51. South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 52. India Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 53. Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 54. Australia Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 55. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Type (2021-2032)
Figure 56. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Application (2021-2032)
Figure 57. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Country (2021-2032)
Figure 58. Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 59. Argentina Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 60. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Type (2021-2032)
Figure 61. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Application (2021-2032)
Figure 62. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Country (2021-2032)
Figure 63. Turkey Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 64. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 65. UAE Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 66. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Drivers
Figure 67. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Restraints
Figure 68. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Trends
Figure 69. Porters Five Forces Analysis
Figure 70. Amyotrophic Lateral Sclerosis (ALS) Treatment Industrial Chain
Figure 71. Methodology
Figure 72. Research Process and Data Source
Figure 1. Amyotrophic Lateral Sclerosis (ALS) Treatment Picture
Figure 2. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Type in 2025
Figure 4. Riluzole
Figure 5. Edaravone (Radicava)
Figure 6. Other
Figure 7. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 8. Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Application in 2025
Figure 9. Hospital Picture
Figure 10. Drugs Store Picture
Figure 11. Other Picture
Figure 12. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 13. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 14. Global Market Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 15. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Region (2021-2032)
Figure 16. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Region in 2025
Figure 17. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 18. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 19. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 20. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 21. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 22. Company Three Recent Developments and Future Plans
Figure 23. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Players in 2025
Figure 24. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 25. Market Share of Amyotrophic Lateral Sclerosis (ALS) Treatment by Player Revenue in 2025
Figure 26. Top 3 Amyotrophic Lateral Sclerosis (ALS) Treatment Players Market Share in 2025
Figure 27. Top 6 Amyotrophic Lateral Sclerosis (ALS) Treatment Players Market Share in 2025
Figure 28. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Share by Type (2021-2026)
Figure 29. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share Forecast by Type (2027-2032)
Figure 30. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Share by Application (2021-2026)
Figure 31. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share Forecast by Application (2027-2032)
Figure 32. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Type (2021-2032)
Figure 33. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Application (2021-2032)
Figure 34. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Country (2021-2032)
Figure 35. United States Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 36. Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 37. Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 38. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Type (2021-2032)
Figure 39. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Application (2021-2032)
Figure 40. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Country (2021-2032)
Figure 41. Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 42. France Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 43. United Kingdom Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 44. Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 45. Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 46. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Type (2021-2032)
Figure 47. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Application (2021-2032)
Figure 48. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Region (2021-2032)
Figure 49. China Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 50. Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 51. South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 52. India Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 53. Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 54. Australia Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 55. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Type (2021-2032)
Figure 56. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Application (2021-2032)
Figure 57. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Country (2021-2032)
Figure 58. Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 59. Argentina Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 60. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Type (2021-2032)
Figure 61. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Application (2021-2032)
Figure 62. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Country (2021-2032)
Figure 63. Turkey Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 64. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 65. UAE Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value (2021-2032) & (USD Million)
Figure 66. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Drivers
Figure 67. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Restraints
Figure 68. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Trends
Figure 69. Porters Five Forces Analysis
Figure 70. Amyotrophic Lateral Sclerosis (ALS) Treatment Industrial Chain
Figure 71. Methodology
Figure 72. Research Process and Data Source
